



IPO NOTE

SAI PARENTERAL LIMITED



Rating:

AVOID



ISSUE OFFER

Issue Opens on	MAR 24, 2026
Issue Close on	MAR 27, 2026
Total IPO size (cr)	₹409
Fresh issue (cr)	₹285
Offer For Sale (cr)	₹124
Price Band (INR)	₹ 372-₹ 392
Market Lot	38 SHARES
Face Value (INR)	₹5
Listing At	BSE, NSE
Market Cap (Pre IPO)	₹ 1,731.83 CR

ISSUE BREAK-UP (%)

QIB Portion	<div style="width: 50%;"></div>	50%
NII Portion	<div style="width: 15%;"></div>	15%
Retail Portion	<div style="width: 35%;"></div>	35%

INDICATIVE TIMETABLE

Basis of Allotment	30-03-2026
Refunds/Unblocking ASBA Fund	01-04-2026
Credit of Share to Demat A/c	01-04-2026
Listing Date	02-04-2026

Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.

OBJECTS OF THE ISSUE

- Capacity expansion & manufacturing upgrade
- New R&D centre setup
- Loan repayment.
- Working capital needs
- Subsidiary investment for acquisition
- General corporate purposes

FINANCIALS (RESTATED CONSOLIDATED)

PARTICULARS (IN CRORE)	FY 2025	FY 2024	FY 2023
Equity Share Capital	13.31	13.25	7.15
Net Worth	95.78	76.40	31.49
Revenue	163.74	155.18	97.03
EBITDA Margin%	24.08%	20.43%	18.18%
Net Profit/Loss of the year	14.43	8.42	4.38

FINANCIAL RATIOS OF FY25



9.28%

ROCE



72.19x

P/E (Pre IPO)



5.43

EPS (Pre IPO)

OUTLOOK & VALUATION

- At a pre-IPO P/E of 72.19x and ROCE of only 9.28%, the valuation appears stretched. Peers like Innova Captab trade at 32.45x and Gland Pharma at 44.71x with significantly higher scale and earnings.
- The business fundamentals and growth trajectory are solid, but the P/E of 72x is expensive for a company of this size and ROCE.
- The company entered export markets in FY2023 and currently supplies to Australia, New Zealand, Southeast Asia, the Middle East and Africa, with WHO-GMP and TGA-accredited facilities, which supports a long-term growth thesis.
- Investors seeking short-term/listing gains should avoid. Risk-reward is unfavorable. Better opportunities exist in the pharma sector at more reasonable valuations.



COMPANY PROFILE

- The Company operates across branded generic formulations and contract development and manufacturing (CDMO) services.
- Its product portfolio spans multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, antibiotics, gastroenterology, respiratory care, dermatology, and vitamins and supplements.
- Offerings cover a wide range of dosage forms such as injectables, tablets, capsules, liquid orals and ointments.
- Sai Parenteral has strong capabilities in sterile injectable manufacturing, including dry powder injections, vials, ampoules and pre-filled syringes.
- Its operations are supported by multiple manufacturing facilities in Telangana and Andhra Pradesh, along with in-house research and development capabilities.
- The Company follows an integrated business model, combining product development, manufacturing and customer-centric execution.



COMPETITIVE STRATEGIES

- Expansion into global injectable formulations market
- Capitalise on CDMO opportunity by leveraging manufacturing capabilities with enhanced R&D competences.
- Strengthening presence in Regulated Markets through the upcoming Noumed's manufacturing facility at Adelaide, Australia.
- Focus on new product development to drive future growth
- Grow Branded Generic Formulations business by leveraging opportunities in the international markets
- Expand capabilities through strategic acquisitions.



KEY CONCERNS

- High revenue dependence on injectable formulations
- Manufacturing facilities are concentrated in limited geographies
- Exposure to stringent regulatory inspections and compliance risks
- Dependence on third-party suppliers for key raw materials
- Customer concentration may affect revenue stability



KEY STRENGTHS

- Diversified pharma portfolio across branded generics and CDMO services
- Strong capabilities in sterile injectable manufacturing
- Presence across multiple therapeutic areas and dosage forms
- Promoter-led management with a long operating track record
- Multiple manufacturing facilities supported by in-house R&D

COMPARISON WITH LISTED INDUSTRY PEERS

Name of the Company	EPS (₹ Basic)	P/E	NAV	Revenue (cr.)	RoNW%
Sai Parenteral's Limited	5.43	72.19	35.98	163.1	15.09
Peer Group					
Sai Life Sciences Limited	8.83	107.70	102.12	1694.5	7.99
Innova Captab Limited	22.41	32.45	167.66	1243.6	13.37
Senores Pharmaceuticals Limited	16.12	64.30	176.37	398.2	7.18
Gland Pharma Limited	42.40	44.71	555.41	5616.5	7.63



DISCLAIMER:

The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. ("SIL"). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus ("RHP") issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor's particular circumstances before making any decisions on the investment. The Investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.

Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000

Compliance Officer: Ms. Sheetal Duraphe Email: compliance@swastika.co.in Phone: (0731) 6644 241

Swastika Investmart Limited, SEBI Reg. No. : NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532

CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.